Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

INTERIM PRESIDENT AND CEO

Chief Financial Officer

Chief Scientific Officer

Interim President and CEO

Chief Business Officer

Pres and CEO

Chief Medical Officer

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory dis...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-01	Premium	sold (taxes)	Premium	Premium	Premium	INTERIM PRESIDENT AND CEO
2024-04-01	Premium	acquired	Premium	Premium	Premium	INTERIM PRESIDENT AND CEO
2024-03-04	Premium	bought	Premium	Premium	Premium	-
2024-03-02	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-03-02	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-02	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-03-02	Premium	sold (taxes)	Premium	Premium	Premium	Chief Scientific Officer
2024-03-01	Premium	bought	Premium	Premium	Premium	-
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	Interim President and CEO
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Scientific Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Interim President and CEO
2024-02-01	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-02-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Scientific Officer
2024-02-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Business Officer
2024-02-01	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-01-01	Premium	acquired	Premium	Premium	Premium	Pres and CEO
2024-01-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-01-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-01-01	Premium	sold (taxes)	Premium	Premium	Premium	Pres and CEO
2023-10-23	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2023-09-06	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2023-09-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer

ACRS - Aclaris Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for ACRS